Last reviewed · How we verify
Piperacillin And Tazobactam (Piperacillin Sodium)
Piperacillin and tazobactam is an antibacterial drug combining a penicillin with a beta-lactamase inhibitor.
Piperacillin and tazobactam is a combination intravenous antibacterial indicated for intra-abdominal, nosocomial pneumonia, skin/skin structure, female pelvic, and community-acquired pneumonia infections in adults and pediatric patients 2 months and older. The pharmacodynamic parameter most predictive of efficacy is time above MIC, with both components showing short half-lives (0.68-0.84 hours) and approximately 30% plasma protein binding. Key risks include significant aminoglycoside inactivation in hemodialysis patients, potential acute kidney injury with vancomycin co-administration, and prolonged neuromuscular blockade with certain agents. The drug should be used only for proven or suspected bacterial infections to reduce resistance development.
At a glance
| Generic name | Piperacillin Sodium |
|---|---|
| Sponsor | Pfizer |
| Drug class | Penicillin-class antibacterial with beta-lactamase inhibitor |
| Target | Bacterial cell wall; beta-lactamase enzyme |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1981 |
Mechanism of action
Piperacillin and tazobactam is an antibacterial drug that works by inhibiting bacterial cell wall synthesis and beta-lactamase enzymes. This mechanism of action allows the drug to effectively target and kill a wide range of bacteria, including both Gram-positive and Gram-negative species. The combination of piperacillin and tazobactam provides a synergistic effect, enhancing the drug's antibacterial activity and reducing the risk of resistance development.
Approved indications
- Intra-abdominal infections
- Nosocomial pneumonia
- Skin and skin structure infections
- Female pelvic infections
- Community-acquired pneumonia
Boxed warnings
- PHARMACY BULK PACKAGE-NOT FOR DIRECT INFUSION
Common side effects
- Blood product related allergy
Drug interactions
- Tobramycin (aminoglycosides)
- Probenecid
- Vancomycin
- Heparin or oral anticoagulants
- Vecuronium and other non-depolarizing neuromuscular blockers
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Piperacillin And Tazobactam CI brief — competitive landscape report
- Piperacillin And Tazobactam updates RSS · CI watch RSS
- Pfizer portfolio CI